BioSpace News Archive

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate virtually in the Oph

Startup to use funds to advance its AI-driven design and commercialization of new proteins to enable sustainable solutions

Agreements will Accelerate BryoLogyx’s Path to Clinical Proof-of-Concept Study GMP-Certified Bryostatin-1 to be Synthesized by Albany Molecular Research Inc. DANVILLE, Calif.--( BUSINESS WIRE )-- BryoLogyx Inc. today announced it has entered into two agreements with Neurotrope, Inc. (Nasdaq: NTRP) to acquire Neurotrope’s preclinical data package and drug product for use of bryostatin-1 in an immuno-oncology application, and to supply Neurotro

MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce the establishment of its wholly owned subsidiary MYR Pharmaceuticals France SAS, located in Paris (France) . Today, around 15-20 million peo

Data show the clinical activity of ABBV-3373 and support advancing the development of the platform in rheumatoid arthritis and initiating clinical studies in other immune-mediated diseases[1]

Scipher Medicine, a pioneer in integrating network science with molecular data to match individual patients with the most effective therapies, has appointed Jerry Conway as Senior Vice President of Market Access. He will focus on patient access to Scipher’s precision diagnostic tools beginning with PrismRA®, a first-of-its-kind molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid a

ApiFix, the only posterior motion-preserving scoliosis correction technology available in the U.S., provides unique advantages for treating progressive adolescent idiopathic scoliosis

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced the closing of its previously announced private investment in public equity (PIPE) in the Company.

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that company management will participate in the Virtual Raymond James Human Health Innovations Conference on Wednesday, June 17, 2020. As part of the conference, Anthony Johnson, M.D., Chief Executive Officer of Goldfinch Bio, will participate in a panel on

Hematogenix® announces the offering of COVID-19 antibody testing from blood samples using the Elecsys® Anti-SARS-CoV-2 test developed by Roche. The offering of this test, which the U.S. Food & Drug Administration (FDA) has approved with emergency use authorization 1 , reaffirms Hematogenix’s commitment to the community during t